Key Highlights
- Amgen revealed plans to invest an additional $300 million in expanding its Juncos, Puerto Rico biologics manufacturing plant.
- The Puerto Rico facility serves as a distribution hub for medicines reaching over 60 countries worldwide.
- This investment builds upon more than $650 million previously committed to Puerto Rico operations within the last 12 months.
- Across Puerto Rico, Ohio, California, and North Carolina, Amgen has pledged more than $3.65 billion toward U.S. manufacturing in recent months.
- The announcement follows President Trump’s executive action warning of 100% tariffs on imported branded pharmaceutical products.
Amgen (AMGN) experienced a 1.54% decline on Monday following the company’s announcement of a $300 million investment to enhance its biologics manufacturing operations in Juncos, Puerto Rico.
The pharmaceutical giant plans to use these funds to increase production capabilities and implement cutting-edge manufacturing technologies at the facility, which has operated continuously since its establishment in 1992.
Currently, the Juncos plant serves as a critical distribution point for biologic medications delivered to more than 60 nations. The financial commitment will bolster the existing workforce while generating hundreds of positions in construction during the expansion phase.
CEO Robert Bradway described the expansion as evidence of Amgen’s “ongoing dedication to American manufacturing,” emphasizing its role in securing domestic supply networks and ensuring patients maintain reliable access to critical medications.
Puerto Rico’s Governor Jenniffer González Colón praised the announcement, stating that the investment validates the effectiveness of policies designed to strengthen the island’s biopharmaceutical industry.
This $300 million commitment follows $650 million in previously announced Puerto Rico investments over the past year, which were projected to generate approximately 750 employment opportunities.
Nationwide Manufacturing Expansion Strategy
The Puerto Rico announcement represents one element of a comprehensive domestic investment program. Throughout the past year, Amgen has committed $900 million to operations in Ohio, allocated $600 million toward a science and innovation facility in California, and designated more than $1.5 billion for development in North Carolina.
When combined with the Puerto Rico expansion, Amgen’s total U.S. manufacturing investments over this period surpass $3.65 billion.
Following the implementation of the Tax Cuts and Jobs Act of 2017, Amgen reports having invested over $40 billion in manufacturing infrastructure and research and development initiatives.
Pharmaceutical Industry Faces Tariff Challenge
The timing of this investment coincides with increasing regulatory scrutiny from the Trump administration regarding pharmaceutical imports.
In April, President Trump issued an executive order establishing 100% tariffs on branded pharmaceutical products imported to the United States, unless manufacturers entered into government pricing agreements or pledged to establish domestic production capabilities.
Amgen’s strengthened U.S. manufacturing presence provides strategic positioning in response to these policy developments, although company representatives characterized the Puerto Rico expansion as aligned with long-term supply chain objectives.
As a U.S. territory, Puerto Rico has maintained a pharmaceutical manufacturing presence spanning more than six decades and hosts numerous major drug production facilities.
The Juncos location has functioned as an integral component of Amgen’s operational network since 1992 and maintains a critical position in the company’s worldwide biologics distribution system.
Amgen has yet to announce a definitive completion timeline for the Puerto Rico expansion project.
